Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.080
+0.010 (0.48%)
At close: Jun 26, 2026, 4:00 PM EDT
2.410
+0.330 (15.87%)
After-hours: Jun 26, 2026, 7:38 PM EDT
Alaunos Therapeutics Employees
Alaunos Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,000
Profits / Employee
-$4,215,000
Market Cap
5.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| Genprex | 13 |
| Processa Pharmaceuticals | 12 |
| TransCode Therapeutics | 12 |
| Dermata Therapeutics | 9 |
| Enveric Biosciences | 6 |
TCRT News
- 4 weeks ago - Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies - TheFly
- 4 weeks ago - Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies - GlobeNewsWire
- 5 weeks ago - Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies - TheFly
- 5 weeks ago - Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - GlobeNewsWire
- 6 weeks ago - Alaunos Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Valion Bio Appoints Melinda Lackey as General Counsel - PRNewsWire
- 3 months ago - Alaunos Therapeutics Annual report: Q4 2025 - Filings
- 4 months ago - Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003 - TheFly